ESR1 and ductal breast carcinoma in situ: Similar to invasive breast cancer, ER+/PR+ positive DCIS with this diagnosis have been treated with anti-hormonal therapy and demonstrated to have reduced recurrence of subsequent breast cancer, indicating DCIS lesions in these patients are hormone responsive [26].